Eating Disorders and GLP-1 RAs
PDF Available ?
Yes
Year
2025
Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications
originally developed to treat type 2 diabetes. GLP-1 RAs are now being used as an approved or off-label treatment for weight loss and have been trialled as a treatment for some eating disorders such as binge eating disorder (BED).
There is limited research available to help researchers, clinicians and patients/consumers to understand
the relationships between GLP-1 RAs and eating disorders. However, it is thought that GLP-1 RAs may
negatively impact eating disorder symptomology and treatment in a number of ways.
This factsheet provides information about GLP-1 RAs as well as their possible interaction with eating disorders including physical and psychological impacts. Practice points are provided for clinicians.
« Back to Browse Resources